Wolfe Research Begins Coverage on Structure Therapeutics (NASDAQ:GPCR)

Analysts at Wolfe Research initiated coverage on shares of Structure Therapeutics (NASDAQ:GPCR) in a note issued to investors on Thursday. The firm set a “peer perform” rating on the stock.

Several other research analysts also recently commented on the stock. Citizens Jmp cut their price objective on shares of Structure Therapeutics from $120.00 to $113.00 and set a “market outperform” rating for the company in a report on Friday, February 27th. Morgan Stanley increased their target price on Structure Therapeutics from $120.00 to $125.00 and gave the stock an “overweight” rating in a research report on Friday, December 12th. Stifel Nicolaus lifted their price target on Structure Therapeutics from $50.00 to $90.00 and gave the company a “buy” rating in a research report on Monday, December 8th. Jefferies Financial Group set a $125.00 target price on Structure Therapeutics and gave the stock a “buy” rating in a research note on Thursday, December 11th. Finally, Leerink Partners reaffirmed an “outperform” rating on shares of Structure Therapeutics in a report on Monday, March 16th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $110.00.

Structure Therapeutics Stock Performance

GPCR stock opened at $47.84 on Thursday. The stock has a fifty day moving average of $70.42 and a 200-day moving average of $51.25. Structure Therapeutics has a fifty-two week low of $13.22 and a fifty-two week high of $94.90. The company has a market capitalization of $3.39 billion, a price-to-earnings ratio of -60.55 and a beta of -1.80.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings data on Thursday, February 26th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.14). Equities analysts predict that Structure Therapeutics will post -0.82 EPS for the current year.

Institutional Investors Weigh In On Structure Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Envestnet Asset Management Inc. purchased a new position in Structure Therapeutics during the second quarter worth about $221,000. PNC Financial Services Group Inc. raised its holdings in shares of Structure Therapeutics by 29.1% in the 2nd quarter. PNC Financial Services Group Inc. now owns 4,415 shares of the company’s stock valued at $92,000 after acquiring an additional 994 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Structure Therapeutics by 18.5% in the 2nd quarter. Geode Capital Management LLC now owns 54,181 shares of the company’s stock valued at $1,124,000 after acquiring an additional 8,444 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of Structure Therapeutics during the 2nd quarter valued at about $399,000. Finally, DNB Asset Management AS purchased a new position in shares of Structure Therapeutics during the second quarter worth about $221,000. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.